MXPA05012120A - 2-imidazo-benzotiazoles como ligandos de receptores de adenosina. - Google Patents

2-imidazo-benzotiazoles como ligandos de receptores de adenosina.

Info

Publication number
MXPA05012120A
MXPA05012120A MXPA05012120A MXPA05012120A MXPA05012120A MX PA05012120 A MXPA05012120 A MX PA05012120A MX PA05012120 A MXPA05012120 A MX PA05012120A MX PA05012120 A MXPA05012120 A MX PA05012120A MX PA05012120 A MXPA05012120 A MX PA05012120A
Authority
MX
Mexico
Prior art keywords
lower alkyl
hydrogen
thiophen
benzo
halogen
Prior art date
Application number
MXPA05012120A
Other languages
English (en)
Inventor
Roger David Norcross
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA05012120A publication Critical patent/MXPA05012120A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

La invencion se refiere a 2-imidazo-benzotiazoles de la formula general (I), en donde R1 es fenilo o un heterociclo que contiene N y/u O; R2 es un imidazol o un imidazol anulado, seleccionado del grupo que consiste de las formulas a), b), c), d) o e); R3 es hidrogeno, fenilo, 2,3-dihidro-benzo[1,4] dioxin-6-ilo, benzo[b]tiofen-3-ilo, 3-metil-benzo[b]tiofen-2-ilo, tiofen-2-ilo, tiofen-3-ilo o tiofen-2-il-metilo, R4 es hidrogeno, -(CH2)nO-alquilo inferior o alquilo inferior; R5 es hidrogeno, alquilo inferior, halogeno, morfolinilo, -NR??R????, piperidinilo, sustituido opcionalmente por hidroxi o es pirrolidin-1-ilo; R6 es hidrogeno, bencilo o -(CH2)nO-alquilo inferior, R7 es hidrogeno, -C(O)O-alquilo inferior, -C(O)-C6H4-halogeno, -C(O)-C6H4-alquilo inferior, -C(O)-alquilo inferior, -C(O)-cicloalquilo, -C(O)-NR??R????, -C(O)-(CH2)nO-alquilo inferior, -S(O)2-alquilo inferior, -(CH2)nO-alquilo inferior, -C(O)-piridin-4-ilo, el anillo que puede ser sustituido por alquilo inferior, halogeno-alquilo inferior o por pirrol-1-il-metilo o es -(CH2)n-C(O)NR??R????; R??/R???? son independientemente uno del otro hidrogeno, alquilo inferior o -(CH2)n-tetrahidropiran-4-ilo, X es -CH2-, -NR??????- o -O-; R?????? es hidrogeno, -C(O)-alquilo inferior, -C(O)O-alquilo inferior,-C(O)-C6H4CH3 o bencilo; n es 1 o 2; y a sales de adicion de acido farmaceuticamente aceptables de los mismos. Estos compuestos son ligandos de receptores de adenosina y por lo tanto son adecuados para el tratamiento de enfermedades relacionadas con este receptor.
MXPA05012120A 2003-05-13 2004-05-06 2-imidazo-benzotiazoles como ligandos de receptores de adenosina. MXPA05012120A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03009842 2003-05-13
PCT/EP2004/004843 WO2004101558A1 (en) 2003-05-13 2004-05-06 2-imidazo-benzothiazoles as adenosine receptor ligands

Publications (1)

Publication Number Publication Date
MXPA05012120A true MXPA05012120A (es) 2006-02-08

Family

ID=33395778

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012120A MXPA05012120A (es) 2003-05-13 2004-05-06 2-imidazo-benzotiazoles como ligandos de receptores de adenosina.

Country Status (15)

Country Link
US (1) US7122545B2 (es)
EP (1) EP1636217B1 (es)
JP (1) JP4408291B2 (es)
KR (1) KR100710453B1 (es)
CN (1) CN100372844C (es)
AT (1) ATE407133T1 (es)
AU (1) AU2004238508B2 (es)
BR (1) BRPI0410315A (es)
CA (1) CA2523959A1 (es)
DE (1) DE602004016328D1 (es)
ES (1) ES2313001T3 (es)
MX (1) MXPA05012120A (es)
PL (1) PL1636217T3 (es)
RU (1) RU2340612C2 (es)
WO (1) WO2004101558A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617557A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
TW201018678A (en) * 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
SG10201401169QA (en) * 2009-04-02 2014-05-29 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
JP5651681B2 (ja) * 2009-04-03 2015-01-14 大日本住友製薬株式会社 代謝型グルタミン酸受容体５介在障害の治療のための化合物、およびその使用方法
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
WO2016164565A1 (en) * 2015-04-08 2016-10-13 University Of Delaware Trans-cycloheptenes and hetero-trans-cycloheptenes for bioorthogonal coupling
WO2018193090A2 (en) * 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
TWI791593B (zh) 2017-08-21 2023-02-11 德商馬克專利公司 做為腺苷受體拮抗劑之苯并咪唑衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
US6037473A (en) * 1997-11-13 2000-03-14 Haarmann & Reimer Gmbh Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
DK1221444T3 (da) * 1999-07-02 2005-11-14 Eisai Co Ltd Kondenserede imidazolforbindelser og lægemidler mod diabetes mellitus
CN1234358C (zh) * 2000-06-21 2006-01-04 弗·哈夫曼-拉罗切有限公司 苯并噻唑衍生物
PL1628662T3 (pl) * 2003-05-21 2007-07-31 Hoffmann La Roche Pochodne benzotiazolu i ich zastosowanie w leczeniu chorób związanych z receptorem adenozynowym A2A

Also Published As

Publication number Publication date
PL1636217T3 (pl) 2009-02-27
AU2004238508A1 (en) 2004-11-25
EP1636217A1 (en) 2006-03-22
WO2004101558A1 (en) 2004-11-25
BRPI0410315A (pt) 2006-05-23
AU2004238508B2 (en) 2009-11-19
KR100710453B1 (ko) 2007-04-24
KR20060009928A (ko) 2006-02-01
CN1780831A (zh) 2006-05-31
CA2523959A1 (en) 2004-11-25
EP1636217B1 (en) 2008-09-03
ATE407133T1 (de) 2008-09-15
US7122545B2 (en) 2006-10-17
RU2340612C2 (ru) 2008-12-10
US20040229862A1 (en) 2004-11-18
CN100372844C (zh) 2008-03-05
ES2313001T3 (es) 2009-03-01
JP2006528215A (ja) 2006-12-14
JP4408291B2 (ja) 2010-02-03
RU2005138546A (ru) 2006-07-27
DE602004016328D1 (de) 2008-10-16

Similar Documents

Publication Publication Date Title
CA2532818A1 (en) (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
JP2009513700A5 (es)
JP2013539789A5 (es)
TW200639158A (en) New compounds with therapeutic effect
EA200601235A1 (ru) Производные тиазола
AR037418A1 (es) Derivados de benzotiazol
MXPA05012120A (es) 2-imidazo-benzotiazoles como ligandos de receptores de adenosina.
CZ290807B6 (cs) Heteroarylový amin, způsob jeho přípravy, farmaceutický prostředek a pouľití
RU2350609C2 (ru) Производные бензофурана и бензотиофена, применяемые при лечении гиперпролиферативных заболеваний
RU2005133994A (ru) Оксимные производные и их применение в качестве фармацевтически активных агентов
MX2010001774A (es) Pirrolidin aril-eteres como antagonistas de receptores de nk3.
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
DE602004020730D1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
TW200510377A (en) Novel compound having 4-pyridylalkylthio group as substituent
JP2007503432A5 (es)
AR045791A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
ATE128463T1 (de) Piperidin und pyrrolidin derivate.
TW200510355A (en) Benzoxazepinone derivatives
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
JP2005502687A5 (es)
NO20004271L (no) Benzylpiperazinyl- og benzylpiperidinyletanonderivater, deres fremstilling og deres anvendelse som dopamin D4- reseptorantagonister
KR900003175A (ko) 벤조피라놀 유도체
PL378343A1 (pl) Pochodne benzoksazolu i ich zastosowanie jako ligandów receptora adenozyny
SG164268A1 (en) Quinolin-4-yl derivatives i
TW200505882A (en) Benzothiazole derivatives

Legal Events

Date Code Title Description
FG Grant or registration